Halozyme Therapeutics Inc
Halozyme Therapeutics's GHG Emissions Data Preview
In 2024, Halozyme Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Halozyme Therapeutics has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Halozyme Therapeutics's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Halozyme Therapeutics amounted to 3,461.16 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Halozyme Therapeutics's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Halozyme Therapeutics's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Halozyme Therapeutics were 1,347.71 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
What are Halozyme Therapeutics's Scope 2 emissions?
In 2024, Halozyme Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 2,113.45 tCOâ‚‚e using the location-based method.
What methodology does Halozyme Therapeutics use for Scope 2 reporting?
In 2024, Halozyme Therapeutics reported its Scope 2 emissions using the location-based method.
Halozyme Therapeutics's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
Insights into Halozyme Therapeutics's Value Chain Emissions
In 2024, Halozyme Therapeutics reported 30.46 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of Halozyme Therapeutics includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in , reflecting improved emissions accounting practices and greater transparency across the company's value chain
Halozyme Therapeutics's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Halozyme Therapeutics's Scope 3 emissions?
In 2024, Halozyme Therapeutics reported total Scope 3 emissions of 30.46 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
What categories of Scope 3 emissions does Halozyme Therapeutics disclose?
In 2024, Halozyme Therapeutics reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Halozyme Therapeutics's Scope 3 emissions?
In 2024, the largest contributors to Halozyme Therapeutics's Scope 3 emissions were:
- Upstream Leased Assets (Cat. 8): 30.46 tCOâ‚‚e (100%)
Halozyme Therapeutics's Scope 3 Emissions by Categories
Insights into Halozyme Therapeutics's Total Carbon Footprint
In 2024, Halozyme Therapeutics reported a total carbon footprint of 3,491.62 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions.
The largest contributor to Halozyme Therapeutics's total carbon footprint was Scope 2 emissions, accounting for 60.53% of the company's total carbon footprint, followed by Scope 1 emissions at 38.6%.